TASCENSO ODT Drug Patent Profile
✉ Email this page to a colleague
When do Tascenso Odt patents expire, and when can generic versions of Tascenso Odt launch?
Tascenso Odt is a drug marketed by Cycle and is included in one NDA. There are three patents protecting this drug.
This drug has seven patent family members in seven countries.
The generic ingredient in TASCENSO ODT is fingolimod lauryl sulfate. There are twenty-one drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the fingolimod lauryl sulfate profile page.
DrugPatentWatch® Generic Entry Outlook for Tascenso Odt
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be January 19, 2036. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for TASCENSO ODT?
- What are the global sales for TASCENSO ODT?
- What is Average Wholesale Price for TASCENSO ODT?
Summary for TASCENSO ODT
International Patents: | 7 |
US Patents: | 3 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Drug Prices: | Drug price information for TASCENSO ODT |
What excipients (inactive ingredients) are in TASCENSO ODT? | TASCENSO ODT excipients list |
DailyMed Link: | TASCENSO ODT at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for TASCENSO ODT
Generic Entry Date for TASCENSO ODT*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET, ORALLY DISINTEGRATING;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for TASCENSO ODT
Drug Class | Sphingosine 1-phosphate Receptor Modulator |
Mechanism of Action | Sphingosine 1-Phosphate Receptor Modulators |
US Patents and Regulatory Information for TASCENSO ODT
TASCENSO ODT is protected by four US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of TASCENSO ODT is ⤷ Sign Up.
This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting TASCENSO ODT
Stable fingolimod dosage forms
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF MULTIPLE SCLEROSIS IN PEDIATRIC PATIENTS 10 YEARS OF AGE AND OLDER AND WEIGHING LESS THAN OR EQUAL TO 40 KG
Stable fingolimod dosage forms
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: THE TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS) IN PATIENTS 10 YEARS OF AGE AND OLDER
Stable solid fingolimod dosage forms
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Stable solid fingolimod dosage forms
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cycle | TASCENSO ODT | fingolimod lauryl sulfate | TABLET, ORALLY DISINTEGRATING;ORAL | 214962-001 | Dec 23, 2021 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Cycle | TASCENSO ODT | fingolimod lauryl sulfate | TABLET, ORALLY DISINTEGRATING;ORAL | 214962-002 | Dec 9, 2022 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Cycle | TASCENSO ODT | fingolimod lauryl sulfate | TABLET, ORALLY DISINTEGRATING;ORAL | 214962-001 | Dec 23, 2021 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Cycle | TASCENSO ODT | fingolimod lauryl sulfate | TABLET, ORALLY DISINTEGRATING;ORAL | 214962-001 | Dec 23, 2021 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for TASCENSO ODT
When does loss-of-exclusivity occur for TASCENSO ODT?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 16209466
Patent: Stable solid fingolimod dosage forms
Estimated Expiration: ⤷ Sign Up
Canada
Patent: 74375
Patent: FORME GALENIQUE SOLIDE STABLE DE FINGOLIMOD (STABLE SOLID FINGOLIMOD DOSAGE FORMS)
Estimated Expiration: ⤷ Sign Up
China
Patent: 7530301
Patent: 稳定的固体芬戈莫德剂型 (STABLE SOLID FINGOLIMOD DOSAGE FORMS)
Estimated Expiration: ⤷ Sign Up
European Patent Office
Patent: 47341
Patent: FORME GALÉNIQUE SOLIDE STABLE DE FINGOLIMOD (STABLE SOLID FINGOLIMOD DOSAGE FORMS)
Estimated Expiration: ⤷ Sign Up
Japan
Patent: 18502168
Patent: 安定な固体フィンゴリモド剤形
Estimated Expiration: ⤷ Sign Up
Taiwan
Patent: 1642842
Patent: Stable solid FINGOLIMOD dosage forms
Estimated Expiration: ⤷ Sign Up
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering TASCENSO ODT around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
European Patent Office | 3247341 | FORME GALÉNIQUE SOLIDE STABLE DE FINGOLIMOD (STABLE SOLID FINGOLIMOD DOSAGE FORMS) | ⤷ Sign Up |
Japan | 2018502168 | 安定な固体フィンゴリモド剤形 | ⤷ Sign Up |
Canada | 2974375 | FORME GALENIQUE SOLIDE STABLE DE FINGOLIMOD (STABLE SOLID FINGOLIMOD DOSAGE FORMS) | ⤷ Sign Up |
China | 107530301 | 稳定的固体芬戈莫德剂型 (STABLE SOLID FINGOLIMOD DOSAGE FORMS) | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for TASCENSO ODT
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1613288 | CR 2011 00023 | Denmark | ⤷ Sign Up | PRODUCT NAME: FINGOLIMOD, HERUNDER FINGOLIMOD SOM HYDROCHLORID; REG. NO/DATE: EU/1/11/677/001-004 20110317 |
0627406 | 1190015-6 | Sweden | ⤷ Sign Up | PRODUCT NAME: FINGOLIMOD; REG. NO/DATE: EU/1/11/677/001-04 20110317 |
1613288 | 122011100047 | Germany | ⤷ Sign Up | PRODUCT NAME: FINGOLIMOD ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ HIERVON; NAT. REGISTRATION NO/DATE: FIRST REGISTRATION: EU EU/1/11/677/001-004 20110317EU/1/11/677/001 EU/1/11/677/002 EU/1/11/677/003 EU/1/11/677/004 20110317 |
1613288 | 28/2011 | Austria | ⤷ Sign Up | PRODUCT NAME: FINGOLIMODHYDROCHLORID; REGISTRATION NO/DATE: EU/1/11/677-001-004 20110317 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |